{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:22:27Z","timestamp":1791285747913,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40265-024-02027-2","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T07:01:56Z","timestamp":1713250916000},"page":"579-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo"],"prefix":"10.1007","volume":"84","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"3","key":"2027_CR1","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm M, Schunter JA, Fritz K, et al. S1 guideline: diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365\u201378.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"2027_CR2","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"N van Geel","year":"2023","unstructured":"van Geel N, Speeckaert R, Ta\u00efeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2027_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/cosmetics10030084","volume":"10","author":"K AL-smadi","year":"2023","unstructured":"AL-smadi K, Imran M, Leite-Silva VR, et al. Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics. 2023;10(3):84.","journal-title":"Cosmetics"},{"issue":"10","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 2023;159(10):1124\u20138.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"2027_CR5","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Ta\u00efeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force part 2: specific treatment recommendations. J Eur Dermatol Venerol. 2023;37(11):2185\u201395.","journal-title":"J Eur Dermatol Venerol"},{"issue":"4","key":"2027_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","volume":"142","author":"C Martins","year":"2022","unstructured":"Martins C, Migayron L, Drullion C, et al. Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling. J Investig Dermatol. 2022;142(4):1194-205.e7.","journal-title":"J Investig Dermatol"},{"key":"2027_CR7","unstructured":"Incyte Biosciences Distribution B.V. Opzelura 15 mg\/g cream: EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu. Accessed 20 Mar 2024."},{"key":"2027_CR8","unstructured":"Incyte Biosciences UK Ltd. Opzelura 15mg\/g cream: UK summary of product characteristics. 2023. https:\/\/products.mhra.gov.uk. Accessed 20 Mar 2024."},{"key":"2027_CR9","unstructured":"Incyte Corporation. OPZELURA\u2122 (ruxolitinib) cream, for topical use: US prescribing information. 2022. https:\/\/dailymed.nlm.nih.gov. Accessed 20 Mar 2024."},{"issue":"1","key":"2027_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40257-022-00748-2","volume":"24","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Ruxolitinib cream 1.5%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2023;24(1):143\u201351.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"2027_CR11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1038\/jid.2011.140","volume":"131","author":"JS Fridman","year":"2011","unstructured":"Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Investig Dermatol. 2011;131(9):1838\u201344.","journal-title":"J Investig Dermatol"},{"issue":"119889","key":"2027_CR12","first-page":"1","volume":"590","author":"I Persaud","year":"2020","unstructured":"Persaud I, Diamond S, Pan R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. Int J Pharm. 2020;590(119889):1\u20136.","journal-title":"Int J Pharm"},{"issue":"6","key":"2027_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054-60.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"10244","key":"2027_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"2027_CR15","first-page":"80","volume":"187","author":"JE Harris","year":"2022","unstructured":"Harris JE, Pandya AG, Lebwohl M, et al. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 156-week data from a phase II study [abstract no. P96 plus poster]. Br J Dermatol. 2022;187(Suppl. 1):80\u20131.","journal-title":"Br J Dermatol"},{"issue":"16","key":"2027_CR16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"3","key":"2027_CR17","doi-asserted-by":"publisher","first-page":"AB50","DOI":"10.1016\/j.jaad.2022.06.235","volume":"87","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Ezzedine K, Desai S. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies [abstract no. 35187 plus poster]. J Am Acad Dermatol. 2022;87(3):AB50.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2027_CR18","doi-asserted-by":"publisher","first-page":"AB51","DOI":"10.1016\/j.jaad.2022.06.236","volume":"87","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Ezzedine K, Md P, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: week 24 pooled analysis of the TRuE-V phase 3 studies [abstract no. 34789 plus poster]. J Am Acad Dermatol. 2022;87(3):AB51.","journal-title":"J Am Acad Dermatol"},{"issue":"7 Suppl.","key":"2027_CR19","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.jval.2022.04.204","volume":"25","author":"K Ezzedine","year":"2022","unstructured":"Ezzedine K, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by disease duration and use of prior treatment: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO108 plus poster]. Value Health. 2022;25(7 Suppl.):S324.","journal-title":"Value Health"},{"issue":"7 Suppl.","key":"2027_CR20","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.1016\/j.jval.2022.04.192","volume":"25","author":"AG Pandya","year":"2022","unstructured":"Pandya AG, van Geel N, Butler K, et al. Subgroup analysis of quality of life and treatment satisfaction by baseline patient characteristics: pooled results from two randomized phase 3 studies of ruxolitinib cream for the treatment of vitiligo [abstract no. CO96 plus poster]. Value Health. 2022;25(7 Suppl.):S321\u20132.","journal-title":"Value Health"},{"key":"2027_CR21","doi-asserted-by":"crossref","unstructured":"Harris JE, Rosmarin D, Seneschal J, et al. Facial vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43912 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.","DOI":"10.1016\/j.jaad.2023.07.195"},{"key":"2027_CR22","doi-asserted-by":"crossref","unstructured":"Rosmarin D, Harris JE, Wolkerstorfer A, et al. Total vitiligo area scoring index response maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43938 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.","DOI":"10.1016\/j.jaad.2023.07.961"},{"key":"2027_CR23","doi-asserted-by":"crossref","unstructured":"Ezzedine K, Passeron T, Rosmarin D, et al. Vitiligo noticeability scale score maintenance or shift during 52 weeks of ruxolitinib cream treatment for vitiligo: pooled analysis of the TRuE-V phase 3 studies [abstract no. 43959 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.","DOI":"10.1016\/j.jaad.2023.07.420"},{"key":"2027_CR24","doi-asserted-by":"crossref","unstructured":"Seneschal J, Wolkerstorfer A, Desai SR, et al. Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 pooled subgroup analysis from two randomized phase 3 studies [abstract no. 555 plus poster P1383]. In: 31st European Academy of Dermatology and Venereology (EADV) Congress. 2022.","DOI":"10.1093\/bjd\/ljac106.006"},{"key":"2027_CR25","unstructured":"Seneschal J, Grimes P, Desai SR, et al. Efficacy and safety of ruxolitinib cream in adolescent patients with vitiligo: pooled analysis of the 52-week TRuE-V phase 3 studies. In: Society for Pediatric Dermatology 47th Annual Meeting. 2022."},{"key":"2027_CR26","unstructured":"Seneschal J, Wolkerstorfer A, Ezzedine K, et al. Efficacy and safety of ruxolitinib cream through week 104 in patients with vitiligo: subgroup analysis of the TRuE-V long-term extension phase 3 study [abstract no. 927 plus poster P2229]. In: 32nd European Academy of Dermatology and Venereology (EADV) Congress. 2023."},{"key":"2027_CR27","unstructured":"Rosmarin D, Sebastian M, Amster M, et al. Facial and total vitiligo area scoring index response shift during 104 weeks of ruxolitinib cream treatment for vitiligo: results from the open-label arm of the TRuEV long-term extension phase 3 study [abstract plus presentation]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023."},{"key":"2027_CR28","doi-asserted-by":"crossref","unstructured":"Pandya AG, Ezzedine K, Rosmarin D, et al. Treatment-emergent adverse events of interest for janus kinase inhibitors: pooled analysis of the 52-week TRuE-V phase 3 studies of ruxolitinib cream treatment for vitiligo [abstract no. 43978 plus poster]. In: American Academy of Dermatology (AAD) Annual Meeting. 2023.","DOI":"10.1016\/j.jaad.2023.07.971"},{"issue":"2","key":"2027_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40257-023-00840-1","volume":"25","author":"W Hu","year":"2024","unstructured":"Hu W, Thornton M, Livingston RA. Real-world use of ruxolitinib cream: safety analysis at 1 year. Am J Clin Dermatol. 2024;25(2):327\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2027_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2021","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2021;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"7","key":"2027_CR31","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","volume":"12","author":"H Kitchen","year":"2022","unstructured":"Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb). 2022;12(7):1623\u201337.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"2027_CR32","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jocd.15921","volume":"31","author":"M Ehsan","year":"2023","unstructured":"Ehsan M, Rehman AU, Ayyan M, et al. Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2023;31(1):350\u20133.","journal-title":"J Cosmet Dermatol"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02055-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02027-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02027-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:34:37Z","timestamp":1718951677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02027-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02027-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02055-y","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"19 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02055-y","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02055-y","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}